Jasper Therapeutics, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 76/100
What the filing says
On July 16, 2026, Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals (a complement therapy company) and concurrently raised $132 million in gross proceeds via private placement of non-voting convertible preferred stock, co-led by Affinity Asset Advisors and Ikarian Capital. The combined company plans to advance KP-104 (Phase 2/3 dual complement inhibitor), briquilimab (late-stage anti-KIT antibody), and KP-701 (novel anti-CD79BxCD32B mAb), with cash runway extending to mid-2028. As of June 30, 2026, Jasper held $7.3 million in cash and reported a net loss of $2.8 million for Q2 2026.
Why this rating
$132M financing is 1.76× company market cap; acquisition adds pipeline assets and geographic resources; extends runway; material but integration risk and dilution to existing shareholders unquantified.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.